Allakos Inc. (ALLK)
| Market Cap | 5.64B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -153.48M |
| Shares Out | 49.49M |
| EPS (ttm) | -3.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $107.16 |
| Previous Close | $105.35 |
| Change ($) | 1.81 |
| Change (%) | 1.72% |
| Day's Open | 107.30 |
| Day's Range | 105.39 - 110.18 |
| Day's Volume | 178,541 |
| 52-Week Range | 55.51 - 157.98 |
REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil...
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...
REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell r...
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...
-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression support ing once monthly dosing -- -- Management to host conference call and web...
REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related dise...
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis -- -- Top-line safety and efficacy results from both studies expected in the...
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-r...
-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment --
-- Antolimab (AK002) reduced gastrointestinal symptoms by 64 percent in patients with mast cell gastrointestinal disease -- -- Management to host conference call and webcast today at 5:00 pm ET --
-- Management to host conference call and webcast today at 5:00 pm ET -- REDWOOD CITY, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antol...
Allakos Does It Again; bluebird And Sunesis Data: The Good, Bad And Ugly Of Biopharma
Shares of Allakos Inc. rallied 37% in afternoon trading, to a record high.
REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today anno...
Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.
Investors were enthused about this biotech's positive phase 2 results for its lead investigational therapy, AK002.
Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.
As of late, it has definitely been a great time to be an investor Allakos.
Top Ranked Momentum Stocks to Buy for August 9th
About ALLK
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headqu... [Read more...]
| Industry Biotechnology | IPO Date Jul 19, 2018 |
| CEO Robert Alexander | Employees 125 |
| Stock Exchange NASDAQ | Ticker Symbol ALLK |
Analyst Forecasts
According to 8 analysts, the average rating for Allakos stock is "Buy." The 12-month stock price forecast is 135.88, which is an increase of 26.80% from the latest price.